- Home
- ACIC vs XOMA Comparison
ACIC vs XOMA Comparison
Compare ACIC & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACIC | XOMA |
|---|---|---|
| Founded | 1999 | 1981 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 506.4M | 471.6M |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACIC | XOMA |
|---|---|---|
| Price | $10.50 | $41.91 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $52.50 |
| AVG Volume (30 Days) | ★ 277.9K | 91.2K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 6.33% | N/A |
| EPS Growth | ★ 39.61 | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $335,439,000.00 | N/A |
| Revenue This Year | N/A | $24.59 |
| Revenue Next Year | $1.00 | N/A |
| P/E Ratio | ★ $26.83 | $29.64 |
| Revenue Growth | ★ 13.07 | N/A |
| 52 Week Low | $9.80 | $22.29 |
| 52 Week High | $13.06 | $42.81 |
Technical Indicators
Market Signals| Indicator | ACIC | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 47.22 | 59.80 |
| Support Level | $10.31 | $37.00 |
| Resistance Level | $11.39 | $42.25 |
| Average True Range (ATR) | 0.23 | 0.36 |
| MACD | 0.06 | -0.16 |
| Stochastic Oscillator | 77.53 | 48.48 |
Price Performance
Historical ComparisonAbout ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.